Organigram Global Inc. (OGI) received a recommendation from Institutional Shareholder Services (ISS) to vote FOR the ordinary resolution approving the indirect acquisition of Sanity Group GmbH. The recommendation follows OGI’s earlier disclosure of the transaction and signals institutional support for the deal.
The acquisition is valued at €113.4 million, consisting of €80.0 million in cash and €33.4 million in OGI shares. A potential earn‑out of up to €113.8 million is also included. The shares are priced at C$3.00 each, representing a 71.4 % premium to OGI’s closing price on the TSX on the last unaffected trading date.
Strategically, the deal expands OGI’s presence into the German medical cannabis market, complementing its Canadian operations. ISS cited increased scale, geographic diversification, a stronger balance sheet and enhanced cash‑flow generation as key benefits. The transaction positions OGI as a global pure‑play cannabis company with leadership in two of the world’s largest federally legal markets.
Financially, OGI reported Q1 2026 results of net revenue $63.5 million, up 49 % YoY, and adjusted EBITDA $5.3 million, up 273 % YoY. Sanity Group’s 2025 revenue was €60 million, up from €9 million in 2023, with gross margins improving from 14.5 % to 47.2 %. These figures illustrate the growth potential that the acquisition seeks to capture.
The transaction is financed through a combination of OGI’s cash reserves, a new credit facility from ATB Financial, and a C$65.2 million private placement with British American Tobacco (BAT). BAT will receive OGI shares in lieu of cash for its Sanity stake, deepening its investment in OGI.
Regulatory approvals are pending: the shareholder vote is scheduled for March 30 2026, and the deal requires TSX and German foreign‑investment approvals. The transaction is expected to close in the second quarter of 2026.
ISS’s endorsement has been interpreted by investors as a strong institutional vote of confidence, suggesting that the acquisition is viewed as accretive to OGI’s earnings and market reach. Some analysts have noted valuation concerns, but the premium paid and the strategic fit are seen as mitigating factors.
James Yamanaka, OGI CEO, said, "This transformational acquisition will bring together two market leaders, extend our commercial footprint into Europe, and strengthen our competitive edge in the world's largest federally legal cannabis markets." Finn Hänsel, Sanity Group CEO, added, "Together we are poised to unlock significant growth opportunities, especially as new European markets open to both medical and recreational cannabis programmes."
The deal, if approved, is expected to close in Q2 2026 and could significantly enhance OGI’s revenue base, profitability, and geographic diversification, reinforcing its position as a leading player in the global cannabis industry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.